These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 8334745)

  • 1. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly.
    Dobrashian RD; O'Halloran DJ; Hunt A; Beardwell CG; Shalet SM
    Clin Endocrinol (Oxf); 1993 Jun; 38(6):589-93. PubMed ID: 8334745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy.
    Ho KY; Weissberger AJ
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):75-83. PubMed ID: 8050134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.
    Bates AS; Evans AJ; Jones P; Clayton RN
    Clin Endocrinol (Oxf); 1995 Apr; 42(4):417-23. PubMed ID: 7750196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
    Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.
    Parkinson C; Renehan AG; Ryder WD; O'Dwyer ST; Shalet SM; Trainer PJ
    Clin Endocrinol (Oxf); 2002 Jul; 57(1):59-64. PubMed ID: 12100070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients.
    Murray RD; Peacey SR; Rahim A; Toogood AA; Thorner MO; Shalet SM
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):37-44. PubMed ID: 11167924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M; Gebbie J; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
    Riedel M; Günther T; von zur Mühlen A; Brabant G
    Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency.
    Skjaerbaek C; Frystyk J; Kaal A; Laursen T; Møller J; Weeke J; Jørgensen JO; Sandahl Christiansen J; Orskov H
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):25-33. PubMed ID: 10651750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients.
    Juul A; Main K; Blum WF; Lindholm J; Ranke MB; Skakkebaek NE
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):85-93. PubMed ID: 7519529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1.
    Cotterill AM; Daly F; Holly JM; Hughes SC; Camacho-Hübner C; Abdulla AF; Gale EA; Savage MO
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):567-74. PubMed ID: 8548941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
    Damjanović SS; Petakov MS; Raicević S; Micić D; Marinković J; Dieguez C; Casanueva FF; Popović V
    J Clin Endocrinol Metab; 2000 Jan; 85(1):147-54. PubMed ID: 10634378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly.
    Biermasz NR; Smit JW; van Dulken H; Roelfsema F
    Clin Endocrinol (Oxf); 2002 Mar; 56(3):313-9. PubMed ID: 11940042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.